NU 578 Advanced Pharmacology Midterm Exam Prep
Document | 2026/2027 Edition | 150 Verified Questions - 120
Questions with Answers
NU 578 Units 1-5 Exam 2026-120 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NU 578 Advanced Pharmacology covers Units 1
through 5, encompassing the core principles of pharmacodynamics, pharmacokinetics, and therapeutic
management across major drug classes. With 150 verified questions, it provides an extensive review of
autonomic nervous system pharmacology, cardiovascular and renal pharmacotherapeutics, and central
nervous system agents. Each question is accompanied by a detailed clinical rationale, ensuring a deep
understanding of drug mechanisms, adverse effects, and patient-centered considerations. Designed for
MSN, APRN, and DNP students, this resource is essential for mastering advanced pharmacology and
achieving success on the University of South Alabama exam.
Key Features:
Unit 1: Principles of Pharmacology - Pharmacodynamics, Pharmacokinetics, Drug Interactions, and
Pharmacogenomics
Unit 2: Autonomic Nervous System Pharmacology - Cholinergic, Adrenergic, and Anticholinergic Agents
Unit 3: Cardiovascular Pharmacology - Antihypertensives, Antiarrhythmics, Antianginals, and Heart Failure
Medications
Unit 4: Renal and Endocrine Pharmacology - Diuretics, Antidiabetics, Thyroid and Adrenal Agents
Unit 5: Central Nervous System Pharmacology - Anxiolytics, Antidepressants, Antipsychotics,
Anticonvulsants, and Opioid Analgesics
Clinical Application: Case-based questions integrating drug selection, monitoring, and patient education
Evidence-Based Practice: Rationales aligned with current clinical guidelines and prescribing standards
Safety and Adverse Effects: Identification and management of common and serious drug reactions
Drug Interactions: Mechanisms and clinical implications of major interactions
Special Populations: Considerations for pregnancy, lactation, geriatrics, pediatrics, and renal/hepatic
impairment
Pharmacogenomics: Impact of genetic variations on drug response and metabolism
Prescribing and Monitoring: Practical aspects of initiating, titrating, and discontinuing medications
Comparative Pharmacology: Distinguishing between drug classes and individual agents
Patient Education: Key counseling points for adherence and safety
Ethical and Legal Considerations: Prescriptive authority and controlled substance regulations
Integrated Review: Comprehensive coverage of all Units 1-5 with mixed-format questions
Updates for 2026:
- Updated to reflect the latest 2026-2027 academic year guidelines and standards
- Revised rationales to incorporate current evidence-based practice and clinical guidelines
- Expanded question bank to include 150 verified questions with detailed answers
- Enhanced clinical scenarios to better simulate real-world advanced practice prescribing
- Aligned with the University of South Alabama NU 578 course objectives and exam blueprint
Abstract:
This exam preparation document for NU 578 Advanced Pharmacology is meticulously designed to support
graduate nursing students in mastering the complex principles of pharmacotherapeutics. Covering Units 1 through
Page 1
,5, the content spans foundational pharmacokinetics and pharmacodynamics, autonomic nervous system agents,
cardiovascular and renal pharmacotherapy, and central nervous system drugs. Each of the 150 questions is
presented in a mixed format, including multiple-choice, select-all-that-apply, and clinical case scenarios, with
comprehensive rationales that explain the correct answer and why distractors are incorrect. The document
emphasizes clinical application, enabling students to integrate pharmacological knowledge into patient care
decisions. Special attention is given to safety, drug interactions, and patient-specific factors, ensuring a holistic
approach to prescribing. This resource is an invaluable tool for exam preparation, offering a thorough review that
aligns with the rigorous standards of the MSN, APRN, and DNP programs. By engaging with this material,
students will enhance their critical thinking and clinical reasoning skills, ultimately improving patient outcomes in
advanced practice settings.
Keywords:
Advanced Pharmacology, NU 578, Exam Prep, Pharmacotherapeutics, Clinical Rationales, MSN APRN DNP,
University of South Alabama, 2026/2027
Answer Format:
Each question is followed by the correct answer, a detailed explanation of the underlying pharmacological
principles, and a clinical rationale that links the answer to patient care. Distractor explanations are provided to
clarify common misconceptions and reinforce learning. The format is designed to mimic the exam style and
promote critical thinking.
Compliance Checklist:
Aligned with the University of South Alabama NU 578 course syllabus
Updated to 2026-2027 academic year standards
150 verified questions with accurate answers and rationales
Covers all Units 1-5 comprehensively
Suitable for MSN, APRN, and DNP students
Instant PDF download for immediate access
Content Area Overview:
Content Area Questions Key Topics Weight
Principles of Pharmacology 1-30 Pharmacodynamics, Pharmacokinetics, Drug 20%
Interactions, Pharmacogenomics
Autonomic Nervous System 31-60 Cholinergic Agonists/Antagonists, 20%
Pharmacology Adrenergic Agonists/Antagonists,
Anticholinergics
Cardiovascular Pharmacology 61-90 Antihypertensives, Antiarrhythmics, 20%
Antianginals, Heart Failure Medications
Renal and Endocrine 91-120 Diuretics, Antidiabetics, Thyroid Agents, 20%
Pharmacology Adrenal Agents
Central Nervous System 121-150 Anxiolytics, Antidepressants, 20%
Pharmacology Antipsychotics, Anticonvulsants, Opioid
Analgesics
Page 2
,Q1. A patient on warfarin for atrial fibrillation develops a pulmonary embolism
despite therapeutic INR. Pharmacogenomic testing reveals a CYP2C9*2/*3 genotype
and a VKORC1 A/A haplotype. Which dose adjustment is most appropriate?
A. Increase warfarin dose by 50% to overcome the hypermetabolism
B. Maintain current dose but add a direct oral anticoagulant
C. Decrease warfarin dose and consider alternative anticoagulation
D. Switch to a different vitamin K antagonist with less CYP2C9 metabolism
Correct Answer: C. Decrease warfarin dose and consider alternative anticoagulation
Rationale: CYP2C9*2/*3 and VKORC1 A/A are associated with decreased warfarin
metabolism and increased sensitivity, leading to a lower therapeutic dose requirement.
The breakthrough embolism despite therapeutic INR suggests the target INR may not be
adequate for this patient's risk, so alternative anticoagulation (e.g., DOAC) is often
preferred. Increasing the dose would risk bleeding due to the reduced clearance.
Why Wrong:
A - Increasing the dose would exacerbate bleeding risk because the patient is already
sensitive to warfarin due to reduced CYP2C9 metabolism.
B - Adding a DOAC to warfarin without discontinuing warfarin increases bleeding
risk and is not standard practice.
D - Other vitamin K antagonists (e.g., acenocoumarol) also undergo CYP2C9
metabolism and may have similar pharmacogenetic effects.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
(Anticoagulants) & Ch. 5 (Pharmacogenomics)
Q2. A 56-year-old patient with an EGFR-mutant NSCLC develops progressive
disease after 2 years on osimertinib. Biopsy reveals a MET amplification. Which
targeted therapy is most appropriate?
A. Switch to a first-generation EGFR TKI (erlotinib) to overcome resistance
B. Add a MET inhibitor (e.g., capmatinib) to ongoing osimertinib
C. Discontinue all targeted therapy and initiate platinum-based chemotherapy
D. Increase osimertinib dose to the maximum tolerated dose
Correct Answer: B. Add a MET inhibitor (e.g., capmatinib) to ongoing osimertinib
Rationale: MET amplification is a well-established resistance mechanism to osimertinib in
EGFR-mutant NSCLC. Combining a MET inhibitor (e.g., capmatinib) with osimertinib is a
guideline-recommended strategy. Erlotinib would be ineffective due to the T790M
mutation (if present) and the MET-driven resistance. Chemotherapy may be an option but
is not the first choice when a targeted combination is available.
Why Wrong:
A - Erlotinib is a first-generation EGFR TKI and would not overcome MET-driven
resistance, and may be ineffective if T790M is present.
Page 3
, C - Chemotherapy is a later-line option, but targeted combination therapy is preferred
in the presence of a known resistance mechanism.
D - Increasing osimertinib dose does not address MET amplification and is not a
standard strategy for this resistance mechanism.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 48 (Cancer
Chemotherapy) & NCCN Guidelines for NSCLC
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 32 mL/min) is
on metformin and insulin glargine. HbA1c is 8.4%. Which therapy is most
appropriate to add?
A. Empagliflozin
B. Glyburide
C. Pioglitazone
D. Sitagliptin
Correct Answer: A. Empagliflozin
Rationale: Empagliflozin is an SGLT2 inhibitor that reduces cardiovascular and renal risk
and is preferred in patients with CKD and diabetes, even with eGFR as low as 20-25
mL/min (though glucose-lowering efficacy diminishes). It is renally safe and offers
nephroprotection. Glyburide is contraindicated in severe renal impairment due to
increased hypoglycemia risk. Pioglitazone can cause fluid retention and is less preferred
in CKD. Sitagliptin requires dose adjustment but is not preferred over SGLT2 inhibitors
for cardiovascular/renal benefit.
Why Wrong:
B - Glyburide is contraindicated in advanced CKD due to high risk of prolonged
hypoglycemia from accumulation of active metabolites.
C - Pioglitazone may worsen fluid retention and is not preferred in CKD; it also does
not provide the cardiovascular/renal benefits of SGLT2 inhibitors.
D - Sitagliptin is renally excreted and requires dose adjustment, but it does not confer
the renal/cardiovascular benefits of SGLT2 inhibitors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45
(Antidiabetic Agents) & ADA Standards of Care 2026
Q4. A patient with severe asthma is initiated on omalizumab. Which parameter is
most critical to monitor during the first year of therapy?
A. Serum IgE levels every 3 months to adjust the dose
B. Eosinophil count to predict anaphylaxis risk
C. Peak expiratory flow (PEF) variability to assess response
D. Anti-drug antibodies to detect immunogenicity
Correct Answer: C. Peak expiratory flow (PEF) variability to assess response
Page 4
Document | 2026/2027 Edition | 150 Verified Questions - 120
Questions with Answers
NU 578 Units 1-5 Exam 2026-120 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NU 578 Advanced Pharmacology covers Units 1
through 5, encompassing the core principles of pharmacodynamics, pharmacokinetics, and therapeutic
management across major drug classes. With 150 verified questions, it provides an extensive review of
autonomic nervous system pharmacology, cardiovascular and renal pharmacotherapeutics, and central
nervous system agents. Each question is accompanied by a detailed clinical rationale, ensuring a deep
understanding of drug mechanisms, adverse effects, and patient-centered considerations. Designed for
MSN, APRN, and DNP students, this resource is essential for mastering advanced pharmacology and
achieving success on the University of South Alabama exam.
Key Features:
Unit 1: Principles of Pharmacology - Pharmacodynamics, Pharmacokinetics, Drug Interactions, and
Pharmacogenomics
Unit 2: Autonomic Nervous System Pharmacology - Cholinergic, Adrenergic, and Anticholinergic Agents
Unit 3: Cardiovascular Pharmacology - Antihypertensives, Antiarrhythmics, Antianginals, and Heart Failure
Medications
Unit 4: Renal and Endocrine Pharmacology - Diuretics, Antidiabetics, Thyroid and Adrenal Agents
Unit 5: Central Nervous System Pharmacology - Anxiolytics, Antidepressants, Antipsychotics,
Anticonvulsants, and Opioid Analgesics
Clinical Application: Case-based questions integrating drug selection, monitoring, and patient education
Evidence-Based Practice: Rationales aligned with current clinical guidelines and prescribing standards
Safety and Adverse Effects: Identification and management of common and serious drug reactions
Drug Interactions: Mechanisms and clinical implications of major interactions
Special Populations: Considerations for pregnancy, lactation, geriatrics, pediatrics, and renal/hepatic
impairment
Pharmacogenomics: Impact of genetic variations on drug response and metabolism
Prescribing and Monitoring: Practical aspects of initiating, titrating, and discontinuing medications
Comparative Pharmacology: Distinguishing between drug classes and individual agents
Patient Education: Key counseling points for adherence and safety
Ethical and Legal Considerations: Prescriptive authority and controlled substance regulations
Integrated Review: Comprehensive coverage of all Units 1-5 with mixed-format questions
Updates for 2026:
- Updated to reflect the latest 2026-2027 academic year guidelines and standards
- Revised rationales to incorporate current evidence-based practice and clinical guidelines
- Expanded question bank to include 150 verified questions with detailed answers
- Enhanced clinical scenarios to better simulate real-world advanced practice prescribing
- Aligned with the University of South Alabama NU 578 course objectives and exam blueprint
Abstract:
This exam preparation document for NU 578 Advanced Pharmacology is meticulously designed to support
graduate nursing students in mastering the complex principles of pharmacotherapeutics. Covering Units 1 through
Page 1
,5, the content spans foundational pharmacokinetics and pharmacodynamics, autonomic nervous system agents,
cardiovascular and renal pharmacotherapy, and central nervous system drugs. Each of the 150 questions is
presented in a mixed format, including multiple-choice, select-all-that-apply, and clinical case scenarios, with
comprehensive rationales that explain the correct answer and why distractors are incorrect. The document
emphasizes clinical application, enabling students to integrate pharmacological knowledge into patient care
decisions. Special attention is given to safety, drug interactions, and patient-specific factors, ensuring a holistic
approach to prescribing. This resource is an invaluable tool for exam preparation, offering a thorough review that
aligns with the rigorous standards of the MSN, APRN, and DNP programs. By engaging with this material,
students will enhance their critical thinking and clinical reasoning skills, ultimately improving patient outcomes in
advanced practice settings.
Keywords:
Advanced Pharmacology, NU 578, Exam Prep, Pharmacotherapeutics, Clinical Rationales, MSN APRN DNP,
University of South Alabama, 2026/2027
Answer Format:
Each question is followed by the correct answer, a detailed explanation of the underlying pharmacological
principles, and a clinical rationale that links the answer to patient care. Distractor explanations are provided to
clarify common misconceptions and reinforce learning. The format is designed to mimic the exam style and
promote critical thinking.
Compliance Checklist:
Aligned with the University of South Alabama NU 578 course syllabus
Updated to 2026-2027 academic year standards
150 verified questions with accurate answers and rationales
Covers all Units 1-5 comprehensively
Suitable for MSN, APRN, and DNP students
Instant PDF download for immediate access
Content Area Overview:
Content Area Questions Key Topics Weight
Principles of Pharmacology 1-30 Pharmacodynamics, Pharmacokinetics, Drug 20%
Interactions, Pharmacogenomics
Autonomic Nervous System 31-60 Cholinergic Agonists/Antagonists, 20%
Pharmacology Adrenergic Agonists/Antagonists,
Anticholinergics
Cardiovascular Pharmacology 61-90 Antihypertensives, Antiarrhythmics, 20%
Antianginals, Heart Failure Medications
Renal and Endocrine 91-120 Diuretics, Antidiabetics, Thyroid Agents, 20%
Pharmacology Adrenal Agents
Central Nervous System 121-150 Anxiolytics, Antidepressants, 20%
Pharmacology Antipsychotics, Anticonvulsants, Opioid
Analgesics
Page 2
,Q1. A patient on warfarin for atrial fibrillation develops a pulmonary embolism
despite therapeutic INR. Pharmacogenomic testing reveals a CYP2C9*2/*3 genotype
and a VKORC1 A/A haplotype. Which dose adjustment is most appropriate?
A. Increase warfarin dose by 50% to overcome the hypermetabolism
B. Maintain current dose but add a direct oral anticoagulant
C. Decrease warfarin dose and consider alternative anticoagulation
D. Switch to a different vitamin K antagonist with less CYP2C9 metabolism
Correct Answer: C. Decrease warfarin dose and consider alternative anticoagulation
Rationale: CYP2C9*2/*3 and VKORC1 A/A are associated with decreased warfarin
metabolism and increased sensitivity, leading to a lower therapeutic dose requirement.
The breakthrough embolism despite therapeutic INR suggests the target INR may not be
adequate for this patient's risk, so alternative anticoagulation (e.g., DOAC) is often
preferred. Increasing the dose would risk bleeding due to the reduced clearance.
Why Wrong:
A - Increasing the dose would exacerbate bleeding risk because the patient is already
sensitive to warfarin due to reduced CYP2C9 metabolism.
B - Adding a DOAC to warfarin without discontinuing warfarin increases bleeding
risk and is not standard practice.
D - Other vitamin K antagonists (e.g., acenocoumarol) also undergo CYP2C9
metabolism and may have similar pharmacogenetic effects.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
(Anticoagulants) & Ch. 5 (Pharmacogenomics)
Q2. A 56-year-old patient with an EGFR-mutant NSCLC develops progressive
disease after 2 years on osimertinib. Biopsy reveals a MET amplification. Which
targeted therapy is most appropriate?
A. Switch to a first-generation EGFR TKI (erlotinib) to overcome resistance
B. Add a MET inhibitor (e.g., capmatinib) to ongoing osimertinib
C. Discontinue all targeted therapy and initiate platinum-based chemotherapy
D. Increase osimertinib dose to the maximum tolerated dose
Correct Answer: B. Add a MET inhibitor (e.g., capmatinib) to ongoing osimertinib
Rationale: MET amplification is a well-established resistance mechanism to osimertinib in
EGFR-mutant NSCLC. Combining a MET inhibitor (e.g., capmatinib) with osimertinib is a
guideline-recommended strategy. Erlotinib would be ineffective due to the T790M
mutation (if present) and the MET-driven resistance. Chemotherapy may be an option but
is not the first choice when a targeted combination is available.
Why Wrong:
A - Erlotinib is a first-generation EGFR TKI and would not overcome MET-driven
resistance, and may be ineffective if T790M is present.
Page 3
, C - Chemotherapy is a later-line option, but targeted combination therapy is preferred
in the presence of a known resistance mechanism.
D - Increasing osimertinib dose does not address MET amplification and is not a
standard strategy for this resistance mechanism.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 48 (Cancer
Chemotherapy) & NCCN Guidelines for NSCLC
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 32 mL/min) is
on metformin and insulin glargine. HbA1c is 8.4%. Which therapy is most
appropriate to add?
A. Empagliflozin
B. Glyburide
C. Pioglitazone
D. Sitagliptin
Correct Answer: A. Empagliflozin
Rationale: Empagliflozin is an SGLT2 inhibitor that reduces cardiovascular and renal risk
and is preferred in patients with CKD and diabetes, even with eGFR as low as 20-25
mL/min (though glucose-lowering efficacy diminishes). It is renally safe and offers
nephroprotection. Glyburide is contraindicated in severe renal impairment due to
increased hypoglycemia risk. Pioglitazone can cause fluid retention and is less preferred
in CKD. Sitagliptin requires dose adjustment but is not preferred over SGLT2 inhibitors
for cardiovascular/renal benefit.
Why Wrong:
B - Glyburide is contraindicated in advanced CKD due to high risk of prolonged
hypoglycemia from accumulation of active metabolites.
C - Pioglitazone may worsen fluid retention and is not preferred in CKD; it also does
not provide the cardiovascular/renal benefits of SGLT2 inhibitors.
D - Sitagliptin is renally excreted and requires dose adjustment, but it does not confer
the renal/cardiovascular benefits of SGLT2 inhibitors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45
(Antidiabetic Agents) & ADA Standards of Care 2026
Q4. A patient with severe asthma is initiated on omalizumab. Which parameter is
most critical to monitor during the first year of therapy?
A. Serum IgE levels every 3 months to adjust the dose
B. Eosinophil count to predict anaphylaxis risk
C. Peak expiratory flow (PEF) variability to assess response
D. Anti-drug antibodies to detect immunogenicity
Correct Answer: C. Peak expiratory flow (PEF) variability to assess response
Page 4
